Brodsky & Smith has prompted savers of significant imminent deadlines concerning class action proceedings against Array Technologies, ContextLogic, Danimer Scientific, Inc., f/k/a Live Oak for defilements of central securities rules.
Array Technologies Inc (NASDAQ: ARRY)
Stocks bought between October 14, 2020, and May 11, 2021, or stocks pursuant and/or observable to the October 2020 initial public contribution, the company’s December 2020 contribution, or the March 2021 contribution.
Cutoff date: July 13, 2021
The filed grievance claims that through the Class Period and in the Offerings, the respondents made untrue and/or deceptive declarations and/or botched to reveal: (1) the enduring influence of numerous increasing costs, including prices related to certain provisions such as steel, as well as Array’s cargo costs; and (2) as a consequence of the preceding, Array’s encouraging declarations about its business and processes lacked a sensible foundation.
ContextLogic Inc (NASDAQ: WISH)
Stocks bought between December 16, 2020, and May 12, 2021, or pursuant or definite to ContextLogic’s December 16, 2020, early public stock contribution
Deadline: July 16, 2021
According to the filed grievance, the respondents botched to reveal and distorted the subsequent opposing facts that occurred at the time of the IPO: (1) ContextLogic’s fourth-quarter 2020 once-a-month energetic users had deteriorated substantially and were not than rising; and (2) as a consequence of the preceding, the respondents substantially exaggerated ContextLogic’s business metrics and monetary forecasts.
Danimer Scientific Inc f/k/a Live Oak Acquisition Corp. (NYSE: DNMR)
Shares bought between October 5, 2020, and May 4, 2021
Cutoff date: July 13, 2021
Rendering to the filed grievance, throughout the Class Period, the respondents made untrue and/or deceptive declarations and/or failed to disclose that: (1) the respondents exaggerated and/or misstated the biodegradability and environmentally-friendly nature of its Nodax creation; (2) the respondents distorted the extent of Danimer’s amenities, production volume, and definite manufacture quantities, and charges; (3) the respondents distorted Danimer’s growth, monetary consequences, and financial forecasts; (4) Danimer had incomplete internal controls; and (5) as a consequence, Danimer’s public declarations were substantially untrue and deceptive at all pertinent times.
Pomerantz Law Firm Examines entitlements On Behalf of Savers of Washington Prime Group, Inc
Pomerantz LLP is examining rights on behalf of savers of Washington Prime Group Inc (NYSE: WPG). The inquiry concerns whether WPG and certain representatives and/or bosses have participated in securities deception or other illegal business practices.
On February 16, 2021, WPG exposed that its working conglomerate, WPG L.P., had “selected to overturn an interest amount of $23.2 million owing on February 15, 2021 with respect to WPG L.P.’s unresolved Senior Notes due 2024,” and that “WPG L.P. has a 30-day grace period to make the interest payment before such nonpayment establishes an ‘event of evasion.'” The company additional counseled that, in the event of nonpayment, positive counterparties to the senior notes “could hurry the unresolved obligation owing , making such obligation unpaid and owed, which would consequence in a cross-default with respect to some of WPG L.P.’s or the company’s other obligation.”
Law Workplaces of Howard G. Smith Prompts Savers of Class Actions on Behalf of Stockholders
Law Workplaces of Howard G. Smith reminds investors that class action proceedings have been filed on behalf of stockholders of Provention Bio, Inc., Washington Prime Group, Inc, and Virgin Galactic Holdings, Inc. Shareholders have until the deadline date recorded below to record a principal plaintiff motion.
Provention Bio Inc (NASDAQ: PRVB)
Class Dates: November 2, 2020, to April 8, 2021
Lead Plaintiff Deadline: July 20, 2021
On April 8, 2021, Provention Bio distributed a media announcement “announcing that the company gained a report on April 2, 2021 from the [FDA], declaring that, as part of its continuing assessment of the company’s [BLA] for teplizumab. The notification was for the rescheduling or preemption of medical [T1D], the FDA has documented deficiencies that foil dialogue of cataloguing and post-marketing supplies/potentials at this time.”
The complaint asserts that, through the Class Period, respondents made dishonest and misleading assertions and failed to disclose that:
Provention Bio’s teplizumab BLA lacked its agreed procedure and would necessitate additional facts to secure FDA authorization.
So, Provention Bio’s teplizumab BLA required the evidentiary support Provention Bio had led investors to trust it possessed.
Provention Bio had overstated the teplizumab BLA’s confirmation predictions and the commercialization timeline for teplizumab.
As a concern, Provention Bio’s public statements were significantly untrue and misleading at all relevant whiles.
Washington Prime Group Inc (NYSE: WPG)
Class Dates: November 5, 2020, to March 4, 2021
Lead Plaintiff Deadline: July 23, 2021
On February 16, 2021, WPG revealed that its operational enterprise, Washington Prime Group, L.P., had “selected to hold back an interest amount of $23.2 million unresolved on February 15, 2021 with respect to WPG L.P.’s unresolved Senior Notes due 2024,” and that “WPG L.P. has a 30-day leniency period to make the interest sum before such nonpayment constitutes an ‘occurrence of nonpayment.'” The company further counseled that, in the event of avoidance, definite counterparties to the older notes “could hurry the unsettled commitment due . . . making such debt outstanding and owed, which would result in a cross-default with respect to some of WPG L.P.’s or the company’s other debt.”
The grievance filed in this class action claims that through the Class Period, defendants made considerably false or misleading declarations, as well as miscarried to disclose substantial contrary actualities about the company’s trade, procedures, and predictions. Specifically, defendants miscarried to disclose to depositors: (1) that WPG’s fiscal state was deteriorating significantly; (2) that, as a concern, there was substantial uncertainty about the company’s ability to meet its capital organization answerabilities as they become due; and (3) that, as a result of the previous, Respondents’ positive declarations about the company’s commercial, procedures, and forecasts were considerably misleading or required a sensible foundation.
Virgin Galactic Holdings Inc (NYSE: SPCE)
Class Dates: October 26, 2019, to April 30, 2021
Lead Petitioner Cutoff date: July 27, 2021
On October 25, 2019, post-market, Virgin Galactic was formed over a viable consortium amid Social Capital Hedosophia Holdings Corp. and Legacy Virgin Galactic. Consequently, SCH changed its title to “Virgin Galactic Holdings, Inc.” and its ticker sign to “SPCE.”
On April 12, 2021, SEC sent a notification that averring SPAC securities might need to be considered debts rather than equity for many SPAC transactions, which had earlier been accounted for as equity in these transactions.
Through the Class Period, defendants made considerably false and misleading declarations regarding the company’s business, procedures, and acquiescence policies. Precisely, defendants made misleading declarations or failed to divulge that:
For bookkeeping drives, SCH’s sureties were essential to be treated as liabilities reasonably than equities.
Virgin Galactic had imperfect disclosure controls and activities and internal control over financial reporting.
Accordingly, the company improperly accounted for SCH securities that were unresolved at the while of the Business Combination.
As a consequence, the company’s public statements were considerably incorrect and misleading at all pertinent times.
Ocugen Inc (NASDAQ: OCGN)
Discussion Dates: February 2, 2021 – June 10, 2021
Lead Plaintiff Deadline: August 16, 2021
The complaint filed claims that throughout the Class Period, Respondents made substantially untrue and deceptive statements and botched to disclose material adverse facts about the company’s business, processes, and forecasts. Exactly, Respondents messed up to reveal to investors that:
- The info submitted to the FDA was inadequate to sustenance a EUA.
- Ocugen would not file a Crisis Use Endorsement with the FDA.
- As a result, Respondents’ declarations about its business, processes, and forecasts were substantially untrue and deceptive and lacked a reasonable basis at all pertinent times.